Nano-X Imaging Ltd. NNOX Financial Statement Data

2025 Q2

Submissions

Field	Row 1
adsh	0001213900-25-030318
cik	1795251
name	NANO-X IMAGING LTD.
sic	3844
countryba	IL
stprba
cityba	PETACH TIKVA
zipba	4970602
bas1	OFER TECH PARK
bas2	94 SHLOMO SHMELTZER ROAD
baph	972-37359202
countryma	IL
stprma
cityma	PETACH TIKVA
zipma	4970602
mas1	OFER TECH PARK
mas2	94 SHLOMO SHMELTZER ROAD
countryinc	IL
stprinc
ein	000000000
former
changed
afs	2-ACC
wksi	0
fye	1231
form	20-F
period	20241231
fy	2024
fp	FY
filed	20250409
accepted	2025-04-09 16:30:00.0
prevrpt	0
detail	1
instance	ea0233444-20f_nanox_htm.xml
nciks	1
aciks

Description

Field Name	Field Description
adsh	Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik	Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name	Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic	Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba	The ISO 3166-1 country of the registrant's business address.
stprba	The state or province of the registrant’s business address, if field countryba is US or CA.
cityba	The city of the registrant's business address.
zipba	The zip code of the registrant’s business address.
bas1	The first line of the street of the registrant’s business address.
bas2	The second line of the street of the registrant’s business address.
baph	The phone number of the registrant’s business address.
countryma	The ISO 3166-1 country of the registrant's mailing address.
stprma	The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma	The city of the registrant's mailing address.
zipma	The zip code of the registrant’s mailing address.
mas1	The first line of the street of the registrant’s mailing address.
mas2	The second line of the street of the registrant’s mailing address.
countryinc	The ISO 3166-1 country of incorporation for the registrant.
stprinc	The state or province of incorporation for the registrant, if countryinc is US or CA.
ein	Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former	Most recent former name of the registrant, if any.
changed	Date of change from the former name, if any.
afs	Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi	Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye	Fiscal Year End Date, rounded to nearest month-end.
form	The submission type of the registrant’s filing.
period	Balance Sheet Date, rounded to nearest month-end.
fy	Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp	Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed	The date of the registrant’s filing with the Commission.
accepted	The acceptance date and time of the registrant’s filing with the Commission.
prevrpt	Previous Report – TRUE indicates that the submission information was subsequently amended.
detail	TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance	The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks	Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks	Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh	ddate	tag	value	uom	qtrs	version	segments	footnote
0001213900-25-030318	20241231	Accounts Payable Current	2209000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Depreciation	998000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Amortization Of Premium Discount And Accrued Interest On Marketable Securities	260000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Assets	66274000.0000	USD	0	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	38529000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect	-28243000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect	17848000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Change In Contingent Earnout Liability	4488000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Comprehensive Income Net Of Tax	-59107000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Comprehensive Income Net Of Tax	-53212000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Cost Of Revenue	99000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	Deferred Income Tax Expense Benefit	-377000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Deferred Income Tax Expense Benefit	-377000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Depreciation	905000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Depreciation	115000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	-60000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	18661000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Developed Technology Rights;
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	1550000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Trade Names;
0001213900-25-030318	20231231	Gain Loss On Sale Of Property Plant Equipment	-1297000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	General And Administrative Expense	12721000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20221231	General And Administrative Expense	1832000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	General And Administrative Expense	22455000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Goodwill Impairment Loss	7055000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= A I Solutions; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of U S A R A D;
0001213900-25-030318	20231231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Radiology Services; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20231231	Goodwill Impairment Loss	7055000.0000	USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Radiology Services; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of U S A R A D;
0001213900-25-030318	20221231	Gross Profit	-6880000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Gross Profit	1422000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20221231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest	-61115000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest	-53874000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Income Tax Expense Benefit	-339000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Accounts Payable Trade	469000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Inventories	277000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Other Noncurrent Assets	251000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders	18617000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Us		USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Usin Shares	190000.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20231231	Marketable Securities Current	26006000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Marketable Securities Current	26006000.0000	USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20221231	Net Cash Provided By Used In Financing Activities	804000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Operating Income Loss	-117710000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1	320000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Operating Lease Liability Current	861000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Other Assets Current	1092000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Other Assets Current	1349000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Other Operating Income Expense Net	-8191000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Payment Due To Settlement Of Contingent Earnout Liabilities		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Payments To Acquire Property Plant And Equipment	3303000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Prepaid Expense Current	827000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Proceeds From Long Term Deposits	10000000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Proceeds From Sale And Maturity Of Marketable Securities	822000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Reclassification Of Earnout Liability To Equity		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Reclassifications Of Temporary To Permanent Equity		USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Research And Development Expense	118000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Research And Development Expense	3856000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Selling And Marketing Expense	4376000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Selling And Marketing Expense	997000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	Selling And Marketing Expense	454000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20221231	Stockholders Equity	158000.0000	USD	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stockholders Equity	165000.0000	USD	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stockholders Equity	-320233000.0000	USD	0	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	7000.0000	USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Value Other	27139000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Stock Issued During Period Value Stock Options Exercised	578000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20241231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Stock Issued During Period Value Stock Options Exercised	2000.0000	USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Temporary Equity Shares Outstanding	57778628.0000	shares	0	us-gaap/2024
0001213900-25-030318	20241231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20221231	Weighted Average Number Of Shares Outstanding Basic	52235000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20241231	Accounts And Other Receivables Net Current	1805000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Accrued Liabilities Current	3920000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Additional Paid In Capital Common Stock	562688000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	7313000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20241231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20231231	Amortization Of Premium Discount And Accrued Interest On Marketable Securities	-735000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Assets	210002000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Cash And Cash Equivalents At Carrying Value	56377000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect	-17073000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Change In Contingent Earnout Liability	20376000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Common Stock Par Or Stated Value Per Share	0.0100	ILS	0	us-gaap/2024
0001213900-25-030318	20241231	Common Stock Par Or Stated Value Per Share	0.0100	ILS	0	us-gaap/2024
0001213900-25-030318	20231231	Common Stock Shares Authorized	100000000.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Common Stock Shares Issued	63762001.0000	shares	0	us-gaap/2024
0001213900-25-030318	20231231	Revenues	9462000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Common Stock Shares Outstanding	57778628.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Common Stock Value	165000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Comprehensive Income Net Of Tax	-114610000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Cost Of Revenue	8333000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Deferred Income Tax Liabilities Net	2953000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Depreciation	150000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Earnings Per Share Basic	-1.0800	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	856000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Customer Relationships;
0001213900-25-030318	20221231	Foreign Currency Transaction Gain Loss Before Tax	47000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Foreign Currency Transaction Gain Loss Before Tax	-69000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Gain Loss On Investments		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Gain Loss On Sale Of Property Plant Equipment	-202000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Goodwill Impairment Loss	7420000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Goodwill Impairment Loss	365000.0000	USD	4	us-gaap/2024	Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20231231	Gross Profit	-8006000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	Gross Profit	1611000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Income Taxes Paid Net	53000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Accounts Payable Trade	-153000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Accounts Payable Trade	-1316000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Accrued Liabilities And Other Operating Liabilities	10410000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Inventories		USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Receivables	-74000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets	14000.0000	USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Us		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Us		USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	1000.0000	USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20241231	Liabilities Current	13972000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Marketable Securities Current		USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20231231	Net Cash Provided By Used In Investing Activities	35433000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Net Cash Provided By Used In Operating Activities	-43385000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Net Income Loss	-53516000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Noncash Purchase Of Property And Equipment		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Noncash Purchase Of Property And Equipment		USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Operating Income Loss	-67066000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Operating Income Loss	-2760000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Other Asset Impairment Charges	365000.0000	USD	4	us-gaap/2024	Related Party Transaction= A I Solutions Reporting Unit;
0001213900-25-030318	20231231	Other Comprehensive Income Loss Before Reclassifications Net Of Tax	178000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Other Comprehensive Income Loss Net Of Tax	304000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Payments To Acquire Equity Method Investments	1010000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Payments To Acquire Equity Method Investments		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Payments To Acquire Equity Method Investments		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Payments To Acquire Marketable Securities		USD	4	us-gaap/2024
0001213900-25-030318	20221231	Payment To Release Ofinvestment In Restricted Deposits		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Proceeds From Issuance Of Common Stock	37834000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Proceeds From Sale And Maturity Of Marketable Securities		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Proceeds From Short Term Deposits	15500000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Property Plant And Equipment Net	42343000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Property Plant And Equipment Net	45355000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Research And Development Expense	20182000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Research And Development Expense	2448000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	Retained Earnings Accumulated Deficit	-320233000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Revenues	327000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Selling And Marketing Expense	710000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	Selling And Marketing Expense	432000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Share Based Compensation	6838000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20241231	Share Based Compensation	7261000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Stockholders Equity	477953000.0000	USD	0	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Stockholders Equity	195514000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Stockholders Equity	189119000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Stockholders Equity	-1000.0000	USD	0	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20240531	Stock Issued During Period Shares Stock Options Exercised	936383.0000	shares	0	us-gaap/2024
0001213900-25-030318	20221231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Unrealized Loss From Availableforsale Securities	-1367000.0000	USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Unrealized Loss From Availableforsale Securities	1669000.0000	USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Unrealized Loss From Availableforsale Securities	304000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Amortization Of Intangible Assets	10607000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Assets	253933000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Assets	57269000.0000	USD	0	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	Assets Current	78680000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Cash And Cash Equivalents At Carrying Value	39304000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20190831	Common Stock Shares Issued	8041936.0000	shares	0	us-gaap/2024	Title Of Individual= Board Of Directors Chairman;
0001213900-25-030318	20231231	Common Stock Shares Issued	57778628.0000	shares	0	us-gaap/2024
0001213900-25-030318	20241231	Common Stock Shares Issued	63762001.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Contract With Customer Liability Current	580000.0000	USD	0	us-gaap/2024		Includes $398 thousand under long term deferred revenue in the Companys consolidated balance sheets as of January 1, 2023.
0001213900-25-030318	20241231	Contract With Customer Liability Current	140000.0000	USD	0	us-gaap/2024		Includes only short term deferred revenue in the Companys consolidated balance sheets as of December 31, 2024 and 2023.
0001213900-25-030318	20241231	Cost Of Revenue	8664000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Earnings Per Share Diluted	-0.9100	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	12728000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Radiologist Relationships;
0001213900-25-030318	20220630	Goodwill Impairment Loss	51243000.0000	USD	1	us-gaap/2024	Related Party Transaction= A I Solutions Reporting Unit;
0001213900-25-030318	20221231	Goodwill Impairment Loss	50878000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Goodwill Impairment Loss	7055000.0000	USD	4	us-gaap/2024	Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of U S A R A D;
0001213900-25-030318	20221231	Gross Profit	-8182000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Gross Profit		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Gross Profit	-7575000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	Gross Profit	-4645000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Increase Decrease In Contract With Customer Liability	-403000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Other Operating Capital Net	125000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Receivables	507000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Interest Income Expense Nonoperating Net	789000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Issuance Of Ordinary Share In Connections With Earnout Liability	953000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Liabilities	20883000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Liabilities And Stockholders Equity	218648000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Liabilities Current	15524000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Marketable Securities Current		USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20231231	Marketable Securities Current	26006000.0000	USD	0	us-gaap/2024	Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20241231	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments	2000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Net Cash Provided By Used In Operating Activities	-44777000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Net Income Loss	-60776000.0000	USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Net Income Loss	-53516000.0000	USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Noncash Purchase Of Property And Equipment	223000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Operating Lease Right Of Use Asset	3843000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20220630	Other Asset Impairment Charges	14338000.0000	USD	1	us-gaap/2024	Related Party Transaction= A I Solutions Reporting Unit;
0001213900-25-030318	20231231	Other Asset Impairment Charges	7055000.0000	USD	4	us-gaap/2024	Related Party Transaction= Radiology Services Reporting Unit;
0001213900-25-030318	20241231	Other Asset Impairment Charges		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Other Operating Income Expense Net	1424000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Payment Due To Settlement Of Contingent Earnout Liabilities		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Payments Of Financing Costs		USD	4	us-gaap/2024
0001213900-25-030318	20221231	Payments To Acquire Marketable Securities	8454000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Payments To Acquire Marketable Securities	33017000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Prepaid Expense Current	1274000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Proceeds From Issuance Of Common Stock	27139000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Proceeds From Stock Options Exercised	579000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Proceeds From Warrant Exercises	370000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Reclassifications Of Temporary To Permanent Equity	1500000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Research And Development Expense	4806000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	Research And Development Expense	20121000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Research And Development Expense	16223000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Restricted Cash Noncurrent	337000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Retained Earnings Accumulated Deficit	-373749000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Revenues	8578000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Share Based Compensation	7261000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20221231	Stockholders Equity	216680000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Stockholders Equity	562688000.0000	USD	0	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20241231	Stockholders Equity	181000.0000	USD	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability		USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	18617000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	1560000.0000	USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	1000.0000	USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20241231	Stock Issued During Period Shares Acquisitions	5046990.0000	shares	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Stock Issued During Period Shares Stock Options Exercised	372159.0000	shares	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Stock Issued During Period Shares Stock Options Exercised	936383.0000	shares	4	us-gaap/2024	Award Type= Restricted Stock Units R S U;
0001213900-25-030318	20231231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Stock Issued During Period Value Stock Options Exercised	1670000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Weighted Average Number Of Shares Outstanding Basic	58673000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20231231	Accounts And Other Receivables Net Current	1484000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Payments To Acquire Property Plant And Equipment	7171000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Proceeds From Warrant Exercises		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Proceeds From Warrant Exercises		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Accounts Receivable Net	55000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	18623000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Assets	130665000.0000	USD	0	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Assets Noncurrent	131322000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations	39304000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20211231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	66772000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	56377000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Change In Contingent Earnout Liability		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Common Stock Shares Authorized	100000000.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Common Stock Shares Outstanding	55094237.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Common Stock Value	181000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Contract With Customer Liability Current	543000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Cost Of Revenue	8525000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Cost Of Revenue	16497000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Cost Of Revenue	227000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20241231	Cost Of Revenue	8302000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Deposits Assets Noncurrent		USD	0	us-gaap/2024
0001213900-25-030318	20221231	Depreciation	275000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Dividends And Interest Paid	90000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Dividends And Interest Paid	140000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Earnings Per Share Basic	-0.9100	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Earnings Per Share Diluted	-2.1700	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	-268000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	21395000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Developed Technology Rights;
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	14322000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Radiologist Relationships;
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	539000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Marketing Related Intangible Assets;
0001213900-25-030318	20231231	General And Administrative Expense	2480000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	General And Administrative Expense	20472000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Goodwill Impairment Loss	7055000.0000	USD	4	us-gaap/2024	Related Party Transaction= Impairment Of The Goodwill Related To The Acquisition Of U S A R A D;
0001213900-25-030318	20231231	Gross Profit	-6592000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Increase Decrease In Other Noncurrent Liabilities	250000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Other Operating Capital Net	-352000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Prepaid Deferred Expense And Other Assets	-1235000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Receivables	321000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Interest Income Expense Nonoperating Net	2870000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Liabilities Noncurrent	6911000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Marketable Securities Current		USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level1; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20221231	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Marketable Securities Unrealized Gain Loss	306000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Net Cash Provided By Used In Financing Activities	27252000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Net Income Loss	-60776000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Operating Income Loss	-16435000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Operating Lease Liability Noncurrent	4045000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Other Asset Impairment Charges	36540000.0000	USD	1	us-gaap/2024	Related Party Transaction= A I Solutions Reporting Unit;
0001213900-25-030318	20221231	Other Asset Impairment Charges	172000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Other Liabilities Noncurrent	612000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Payments Of Financing Costs	145000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Payments Of Financing Costs		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Reclassifications Of Temporary To Permanent Equity		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Restricted Cash Current	46000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Restricted Cash Noncurrent	327000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Revenues	10275000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Share Based Compensation	6838000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20211231	Stockholders Equity	292148000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability	953000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	18610000.0000	USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20240531	Stock Issued During Period Shares Other	5046990.0000	shares	0	us-gaap/2024
0001213900-25-030318	20231231	Stock Issued During Period Value Other	27133000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Stock Issued During Period Value Stock Options Exercised	579000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Accounts Payable Current	3303000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Accumulated Other Comprehensive Income Loss Net Of Tax	-305000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	6838000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Assets	218648000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Assets	132914000.0000	USD	0	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Commitments And Contingencies		USD	0	us-gaap/2024
0001213900-25-030318	20211231	Common Stock Shares Outstanding	51791441.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Cost Of Revenue	6933000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Cost Of Revenue	56000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20241231	Cost Of Revenue	21892000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Deposits Assets Current	15500000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Other Operating Income Expense Net	-90000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Depreciation	19000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Depreciation	12000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Depreciation	1121000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Earnings Per Share Basic	-2.1700	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	80607000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	41125000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Image Big Data;
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	1187000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Marketing Related Intangible Assets;
0001213900-25-030318	20221231	General And Administrative Expense	36797000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	General And Administrative Expense	2626000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	General And Administrative Expense	17825000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	General And Administrative Expense	4139000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20221231	Goodwill Impairment Loss	50878000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Goodwill Impairment Loss	50878000.0000	USD	4	us-gaap/2024	Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20231231	Goodwill Impairment Loss	365000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest	-116921000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Income Taxes Paid Net	3000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Accrued Liabilities And Other Operating Liabilities	490000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Contract With Customer Liability	-82000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Inventories		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Other Noncurrent Assets	-218000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Other Noncurrent Liabilities	129000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Other Operating Capital Net	-209000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Interest Income Expense Nonoperating Net	1652000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Inventory Net	2356000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Inventory Net	1493000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets	37834000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20241231	Marketable Securities Current		USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20241231	Marketable Securities Current	18402000.0000	USD	0	us-gaap/2024	Fair Value By Measurement Frequency= Fair Value Measurements Recurring;	The following tables summarize the amortized cost, unrealized gains and losses, and fair value of available-for-sale marketable securities as of December 31, 2024 and 2023:
0001213900-25-030318	20231231	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments	-178000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Marketable Securities Unrealized Gain Loss	-1367000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Operating Expenses	110830000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Operating Expenses	55997000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Operating Expenses	46137000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Operating Income Loss	-4288000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Operating Income Loss	-3063000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Operating Lease Liability Current	745000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Other Assets Noncurrent	2163000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Proceeds From Sale And Maturity Of Marketable Securities		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Proceeds From Stock Options Exercised	1670000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Research And Development Expense	18891000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Research And Development Expense	26049000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Research And Development Expense	5865000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Revenues		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Revenues	116000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Revenues	281000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Selling And Marketing Expense	3187000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Selling And Marketing Expense	484000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20241231	Selling And Marketing Expense	717000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20221231	Stockholders Equity	-259457000.0000	USD	0	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20231231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	1561000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Stock Issued During Period Shares Stock Options Exercised	746383.0000	shares	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Value Other		USD	4	us-gaap/2024	Equity Components= Retained Earnings;	Issuance expenses totaled to $2,861 in 2023 and $970 in 2024.
0001213900-25-030318	20221231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Stock Issued During Period Value Stock Options Exercised	1668000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20241231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Weighted Average Number Of Diluted Shares Outstanding	56368000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20241231	Accumulated Other Comprehensive Income Loss Net Of Tax	-1000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Amortization Of Intangible Assets	10612000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Assets Current	88635000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations	38529000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Commitments And Contingencies		USD	0	us-gaap/2024
0001213900-25-030318	20221231	Cost Of Revenue	15458000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Deferred Income Tax Liabilities Net	2576000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Depreciation	611000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Dividends And Interest Paid	149000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	642000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Customer Relationships;
0001213900-25-030318	20241231	Gain Loss On Investments	2000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	General And Administrative Expense	3869000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20241231	General And Administrative Expense	491000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Goodwill Impairment Loss	365000.0000	USD	4	us-gaap/2024	Related Party Transaction= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20241231	Goodwill Impairment Loss		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Gross Profit	-8000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest		USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20221231	Income Taxes Paid Net	147000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Contract With Customer Liability	-37000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Prepaid Deferred Expense And Other Assets	-190000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Us		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	370000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	369000.0000	USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Liabilities	23134000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Liabilities And Stockholders Equity	210002000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Long Term Debt Current	3490000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Marketable Securities Current	18402000.0000	USD	0	us-gaap/2024	Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level2; Fair Value By Measurement Frequency= Fair Value Measurements Recurring;
0001213900-25-030318	20231231	Marketable Securities Unrealized Gain Loss	1491000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Net Cash Provided By Used In Investing Activities	14606000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Net Income Loss	-113243000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Net Income Loss	-113243000.0000	USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20231231	Operating Income Loss	-62589000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Operating Income Loss	-56746000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Operating Income Loss	-12092000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1	4411000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Other Comprehensive Income Loss Before Reclassifications Net Of Tax		USD	4	us-gaap/2024
0001213900-25-030318	20221231	Other Comprehensive Income Loss Net Of Tax	-1367000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Other Liabilities Noncurrent	695000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Proceeds From Issuance Of Common Stock		USD	4	us-gaap/2024
0001213900-25-030318	20231231	Proceeds From Sale Of Held To Maturity Securities	38287000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Research And Development Expense	3818000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20231231	Research And Development Expense	63000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Research And Development Expense	103000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Revenues	11283000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Selling And Marketing Expense	479000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Selling And Marketing Expense	2808000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20211231	Stockholders Equity	438820000.0000	USD	0	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20241231	Stockholders Equity	-373749000.0000	USD	0	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Stock Issued During Period Shares Ordinary Shares In Connection With Earnout Liability	89286.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20221231	Stock Issued During Period Shares Ordinary Shares Upon Exercise Of Warrants	192927.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20221231	Stock Issued During Period Value Stock Options Exercised	1000.0000	USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Value Stock Options Exercised	903000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Stock Issued During Period Value Stock Options Exercised	903000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Unrealized Loss From Availableforsale Securities	-1367000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Weighted Average Number Of Diluted Shares Outstanding	58673000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20241231	Accounts Receivable Net	112000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	7313000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Amortization Of Intangible Assets	10612000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Amortization Of Premium Discount And Accrued Interest On Marketable Securities	-1398000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Assets	19819000.0000	USD	0	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Assets Noncurrent	130013000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20190831	Common Stock Shares Issued	10345830.0000	shares	0	us-gaap/2024	Class Of Stock= Common Stock; Range= Maximum;
0001213900-25-030318	20190831	Common Stock Shares Issued	2303894.0000	shares	0	us-gaap/2024	Class Of Stock= Common Stock; Range= Minimum;
0001213900-25-030318	20231231	Common Stock Shares Issued	57778628.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Cost Of Revenue	4926000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Deferred Income Tax Expense Benefit	-3733000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Deposits Assets Noncurrent	10000000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Depreciation	1198000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Depreciation	8000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Earnings Per Share Diluted	-1.0800	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	69995000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Finite Lived Intangible Assets Net	35875000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Image Big Data;
0001213900-25-030318	20241231	Foreign Currency Transaction Gain Loss Before Tax	512000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Gain Loss On Investments	-178000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Gain Loss On Sale Of Property Plant Equipment		USD	4	us-gaap/2024
0001213900-25-030318	20221231	General And Administrative Expense	41254000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	General And Administrative Expense	2625000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	General And Administrative Expense	24272000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Goodwill Impairment Loss		USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Radiology Services; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20231231	Goodwill Impairment Loss	365000.0000	USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= A I Solutions; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20221231	Gross Profit	1302000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20241231	Income Tax Expense Benefit	-358000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Accrued Liabilities And Other Operating Liabilities	-8956000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Increase Decrease In Other Noncurrent Assets	800000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Increase Decrease In Other Noncurrent Liabilities	83000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Increase Decrease In Prepaid Deferred Expense And Other Assets	-1940000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Issuance Of Ordinary Shares Upon Exercise Of R S Us		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Net Cash Provided By Used In Operating Activities	-36598000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Unrealized Loss From Availableforsale Securities	304000.0000	USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20221231	Operating Income Loss	-47884000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20241231	Operating Income Loss	-41591000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Other Asset Impairment Charges		USD	4	us-gaap/2024
0001213900-25-030318	20241231	Other Assets Noncurrent	1792000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Other Comprehensive Income Loss Before Reclassifications Net Of Tax	-2000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Other Comprehensive Income Loss Net Of Tax	1669000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Other Liabilities Current	3849000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Payment Due To Settlement Of Contingent Earnout Liabilities	790000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Payments To Acquire Property Plant And Equipment	2767000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Proceeds From Sale Of Held To Maturity Securities	31241000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Proceeds From Stock Options Exercised	903000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Reclassification Of Earnout Liability To Equity		USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Reclassifications Of Temporary To Permanent Equity		USD	4	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Research And Development Expense	7498000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Revenues	343000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Revenues	9905000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Revenues	727000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Selling And Marketing Expense	4168000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Selling And Marketing Expense	1025000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20231231	Selling And Marketing Expense	2689000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Selling And Marketing Expense	3410000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Selling And Marketing Expense	170000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Share Based Compensation	18623000.0000	USD	4	us-gaap/2024	Award Type= Stock Compensation Plan;
0001213900-25-030318	20211231	Stockholders Equity	-607000.0000	USD	0	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20211231	Stockholders Equity	-146214000.0000	USD	0	us-gaap/2024	Equity Components= Retained Earnings;
0001213900-25-030318	20221231	Stockholders Equity	-1974000.0000	USD	0	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability	953000.0000	USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20230731	Stock Issued During Period Shares Other	2142858.0000	shares	0	us-gaap/2024
0001213900-25-030318	20231231	Stock Issued During Period Shares Stock Options Exercised	251391.0000	shares	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Value Other		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Stock Issued During Period Value Other	6000.0000	USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20241231	Temporary Equity Shares Outstanding	63762001.0000	shares	0	us-gaap/2024
0001213900-25-030318	20231231	Unrealized Loss From Availableforsale Securities	1669000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20221231	Weighted Average Number Of Diluted Shares Outstanding	52235000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20231231	Weighted Average Number Of Shares Outstanding Basic	56368000.0000	shares	4	us-gaap/2024
0001213900-25-030318	20241231	Accrued Liabilities Current	3968000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Additional Paid In Capital Common Stock	515887000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20221231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	18623000.0000	USD	4	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	6838000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Assets	74828000.0000	USD	0	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Assets	148352000.0000	USD	0	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20221231	Assets	30753000.0000	USD	0	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Assets	21709000.0000	USD	0	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations	56377000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Common Stock Shares Authorized	100000000.0000	shares	0	us-gaap/2024
0001213900-25-030318	20241231	Common Stock Shares Authorized	100000000.0000	shares	0	us-gaap/2024
0001213900-25-030318	20241231	Common Stock Shares Outstanding	63762001.0000	shares	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20221231	Cost Of Revenue		USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Cost Of Revenue	124000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20231231	Cost Of Revenue	8040000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20231231	Deposits Assets Current		USD	0	us-gaap/2024
0001213900-25-030318	20231231	Depreciation	1036000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	72000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Finite Lived Intangible Assets Net	1722000.0000	USD	0	us-gaap/2024	Finite Lived Intangible Assets By Major Class= Trade Names;
0001213900-25-030318	20231231	General And Administrative Expense	1174000.0000	USD	4	us-gaap/2024	Business Segments= A I Solutions;
0001213900-25-030318	20221231	Goodwill Impairment Loss	50878000.0000	USD	4	us-gaap/2024	Finite Lived Intangible Assets By Major Class= A I Solutions; Related Party Transactions By Related Party= Impairment Of The Goodwill Related To The Acquisition Of Nanox A I;
0001213900-25-030318	20241231	Marketable Securities Current	18402000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Gross Profit	-10609000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Income Tax Expense Benefit	-3678000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Issuance Of Ordinary Share In Connections With Earnout Liability	1561000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Share In Connections With Earnout Liability		USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets	37820000.0000	USD	4	0001213900-25-030318	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Issuance Of Ordinary Shares Upon Exercise Of R S Usin Share	34750.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Liabilities Noncurrent	7610000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Long Term Debt Current	3061000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20241231	Net Cash Provided By Used In Financing Activities	39504000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Net Cash Provided By Used In Investing Activities	-20051000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20241231	Net Income Loss		USD	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Operating Income Loss	-41866000.0000	USD	4	us-gaap/2024	Business Segments= Nanox A R C;
0001213900-25-030318	20241231	Operating Lease Liability Noncurrent	3640000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Operating Lease Right Of Use Asset	4573000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Other Liabilities Current	3407000.0000	USD	0	us-gaap/2024
0001213900-25-030318	20231231	Payment To Release Ofinvestment In Restricted Deposits	-373000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Payment To Release Ofinvestment In Restricted Deposits	46000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20241231	Proceeds From Sale Of Held To Maturity Securities	41187000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20231231	Reclassification Of Earnout Liability To Equity	1500000.0000	USD	4	0001213900-25-030318
0001213900-25-030318	20231231	Reclassifications Of Temporary To Permanent Equity	1500000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20221231	Research And Development Expense	26507000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20241231	Restricted Cash Current		USD	0	us-gaap/2024
0001213900-25-030318	20221231	Revenues	8235000.0000	USD	4	us-gaap/2024	Business Segments= Radiology Services;
0001213900-25-030318	20221231	Share Based Compensation	18623000.0000	USD	4	us-gaap/2024
0001213900-25-030318	20211231	Stockholders Equity	149000.0000	USD	0	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stockholders Equity	-305000.0000	USD	0	us-gaap/2024	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20231231	Stockholders Equity	515887000.0000	USD	0	us-gaap/2024	Equity Components= Additional Paid In Capital;
0001213900-25-030318	20231231	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd		USD	4	0001213900-25-030318	Equity Components= Accumulated Other Comprehensive Income;
0001213900-25-030318	20221231	Stock Issued During Period Shares Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A Il Ltd	2648424.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Shares Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A Il Ltd	255392.0000	shares	4	0001213900-25-030318	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Shares Other	2142858.0000	shares	4	us-gaap/2024	Equity Components= Common Stock;
0001213900-25-030318	20231231	Stock Issued During Period Value Stock Options Exercised		USD	4	us-gaap/2024	Equity Components= Common Stock;	Less than $1.
0001213900-25-030318	20241231	Unrealized Loss From Availableforsale Securities		USD	4	0001213900-25-030318	Equity Components= Retained Earnings;

Description

Field Name	Field Description
adsh	Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag	The unique identifier (name) for a tag in a specific taxonomy release.
version	For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate	The end date for the data value, rounded to the nearest month end.
qtrs	The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom	The unit of measure for the value.
segments	Tags used to represent axis and member reporting.
coreg	If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value	The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote	The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag	version	custom	datatype	iord	crdr	tlabel	doc
Stock Issued During Period Value Stock Options Exercised	us-gaap/2024	0	monetary	D	C	Stock Issued During Period, Value, Stock Options Exercised	Value of stock issued as a result of the exercise of stock options.
Payments To Acquire Equity Method Investments	us-gaap/2024	0	monetary	D	C	Payments to Acquire Equity Method Investments	The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.
Assets Current	us-gaap/2024	0	monetary	I	D	Assets, Current	Amount of asset recognized for present right to economic benefit, classified as current.
Increase Decrease In Other Noncurrent Assets	us-gaap/2024	0	monetary	D	C	Increase (Decrease) in Other Noncurrent Assets	Amount of increase (decrease) in noncurrent assets classified as other.
Operating Lease Liability Current	us-gaap/2024	0	monetary	I	C	Operating Lease, Liability, Current	Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1	0001213900-25-030318	1	monetary	D	D	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1	Represents the amount of operating lease liabilities arising from obtaining operating right-of use assets.
Increase Decrease In Accounts Payable Trade	us-gaap/2024	0	monetary	D	D	Increase (Decrease) in Accounts Payable, Trade	Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
Issuance Of Ordinary Share In Connections With Earnout Liability	0001213900-25-030318	1	monetary	D	C	Issuance Of Ordinary Share In Connections With Earnout Liability	The amount of issuance of ordinary shares in connection with earnout liability.
Marketable Securities Unrealized Gain Loss	us-gaap/2024	0	monetary	D	C	Marketable Security, Unrealized Gain (Loss)	Amount of unrealized gain (loss) on investment in marketable security.
Other Comprehensive Income Loss Before Reclassifications Net Of Tax	us-gaap/2024	0	monetary	D	C	Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	Amount after tax, before reclassification adjustments of other comprehensive income (loss).
Payments To Acquire Property Plant And Equipment	us-gaap/2024	0	monetary	D	C	Payments to Acquire Property, Plant, and Equipment	The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Comprehensive Income Net Of Tax	us-gaap/2024	0	monetary	D	C	Comprehensive Income (Loss), Net of Tax, Attributable to Parent	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Unrealized Loss From Availableforsale Securities	0001213900-25-030318	1	monetary	D	C	Unrealized Loss From Availableforsale Securities	Unrealized loss from available-for-sale securities.
Gain Loss On Investments	us-gaap/2024	0	monetary	D	C	Gain (Loss) on Investments	Amount of realized and unrealized gain (loss) on investment.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest	us-gaap/2024	0	monetary	D	C	Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Increase Decrease In Contract With Customer Liability	us-gaap/2024	0	monetary	D	D	Increase (Decrease) in Contract with Customer, Liability	Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
Interest Income Expense Nonoperating Net	us-gaap/2024	0	monetary	D	C	Interest Income (Expense), Nonoperating	Amount of interest income (expense) classified as nonoperating.
Liabilities	us-gaap/2024	0	monetary	I	C	Liabilities	Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity	us-gaap/2024	0	monetary	I	C	Liabilities and Equity	Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Proceeds From Stock Options Exercised	us-gaap/2024	0	monetary	D	D	Proceeds from Stock Options Exercised	Amount of cash inflow from exercise of option under share-based payment arrangement.
Retained Earnings Accumulated Deficit	us-gaap/2024	0	monetary	I	C	Retained Earnings (Accumulated Deficit)	Amount of accumulated undistributed earnings (deficit).
Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	0001213900-25-030318	1	monetary	D	C	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	Issuance of ordinary shares value upon exercise of warrants.
Common Stock Par Or Stated Value Per Share	us-gaap/2024	0	perShare	I		Common Stock, Par or Stated Value Per Share	Face amount or stated value per share of common stock.
Common Stock Shares Outstanding	us-gaap/2024	0	shares	I		Common Stock, Shares, Outstanding	Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit	us-gaap/2024	0	monetary	D	D	Income Tax Expense (Benefit)	Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Increase Decrease In Receivables	us-gaap/2024	0	monetary	D	C	Increase (Decrease) in Receivables	The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
Net Income Loss	us-gaap/2024	0	monetary	D	C	Net Income (Loss) Attributable to Parent	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Prepaid Expense Current	us-gaap/2024	0	monetary	I	D	Prepaid Expense, Current	Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
Restricted Cash Current	us-gaap/2024	0	monetary	I	D	Restricted Cash, Current	Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stockholders Equity	us-gaap/2024	0	monetary	I	C	Equity, Attributable to Parent	Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Weighted Average Number Of Diluted Shares Outstanding	us-gaap/2024	0	shares	D		Weighted Average Number of Shares Outstanding, Diluted	The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Issuance Of Ordinary Shares Upon Exercise Of R S Usin Shares	0001213900-25-030318	1	shares	D		Issuance Of Ordinary Shares Upon Exercise Of RSUsin Shares	Issuance of ordinary shares upon exercise of RSUs in Shares.
Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments	us-gaap/2024	0	monetary	D	C	Marketable Security, Realized Gain (Loss)	Amount of realized gain (loss) on investment in marketable security.
Accounts Receivable Net	us-gaap/2024	0	monetary	I	D	Accounts Receivable, after Allowance for Credit Loss	Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.
Accumulated Other Comprehensive Income Loss Net Of Tax	us-gaap/2024	0	monetary	I	C	Accumulated Other Comprehensive Income (Loss), Net of Tax	Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets	us-gaap/2024	0	monetary	I	D	Assets	Amount of asset recognized for present right to economic benefit.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations	us-gaap/2024	0	monetary	I	D	Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations	Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Common Stock Shares Issued	us-gaap/2024	0	shares	I		Common Stock, Shares, Issued	Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Earnings Per Share Diluted	us-gaap/2024	0	perShare	D		Earnings Per Share, Diluted	The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	us-gaap/2024	0	monetary	D	D	Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations	Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Gross Profit	us-gaap/2024	0	monetary	D	C	Gross Profit	Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Operating Lease Right Of Use Asset	us-gaap/2024	0	monetary	I	D	Operating Lease, Right-of-Use Asset	Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent	us-gaap/2024	0	monetary	I	D	Other Assets, Noncurrent	Amount of noncurrent assets classified as other.
Selling And Marketing Expense	us-gaap/2024	0	monetary	D	D	Selling and Marketing Expense	The aggregate total amount of expenses directly related to the marketing or selling of products or services.
Amortization Of Premium Discount And Accrued Interest On Marketable Securities	0001213900-25-030318	1	monetary	D	C	Amortization Of Premium Discount And Accrued Interest On Marketable Securities	Represents the amount of amortization of premium, discount and accrued interest on marketable securities.
Change In Contingent Earnout Liability	0001213900-25-030318	1	monetary	D	C	Change In Contingent Earnout Liability	Represents the amount of change in contingent earnout liability.
Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders	0001213900-25-030318	1	monetary	D	C	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders	The amount of issuance of ordinary shares under settlement agreement with former shareholders
Issuance Of Ordinary Shares Upon Exercise Of R S Us	0001213900-25-030318	1	monetary	D	C	Issuance Of Ordinary Shares Upon Exercise Of RSUs	Issuance of ordinary shares upon exercise of RSUs.
Proceeds From Long Term Deposits	0001213900-25-030318	1	monetary	D	C	Proceeds From Long Term Deposits	Amount proceeds from long term deposits.
Accrued Liabilities Current	us-gaap/2024	0	monetary	I	C	Accrued Liabilities, Current	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Stock Issued During Period Ordinary Shares In Connection With Earnout Liability	0001213900-25-030318	1	monetary	D	C	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability	Value of stock issued during ordinary shares in connection with earnout liability.
Cost Of Revenue	us-gaap/2024	0	monetary	D	D	Cost of Revenue	The aggregate cost of goods produced and sold and services rendered during the reporting period.
Goodwill Impairment Loss	us-gaap/2024	0	monetary	D	D	Goodwill, Impairment Loss	Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Increase Decrease In Other Operating Capital Net	us-gaap/2024	0	monetary	D	C	Increase (Decrease) in Other Operating Assets and Liabilities, Net	Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.
Liabilities Current	us-gaap/2024	0	monetary	I	C	Liabilities, Current	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Marketable Securities Current	us-gaap/2024	0	monetary	I	D	Marketable Securities, Current	Amount of investment in marketable security, classified as current.
Other Operating Income Expense Net	us-gaap/2024	0	monetary	D	C	Other Operating Income (Expense), Net	The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
Proceeds From Sale And Maturity Of Marketable Securities	us-gaap/2024	0	monetary	D	D	Proceeds from Sale and Maturity of Marketable Securities	The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.
Reclassifications Of Temporary To Permanent Equity	us-gaap/2024	0	monetary	D	C	Reclassifications of Temporary to Permanent Equity	The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.
Share Based Compensation	us-gaap/2024	0	monetary	D	D	Share-Based Payment Arrangement, Noncash Expense	Amount of noncash expense for share-based payment arrangement.
Noncash Purchase Of Property And Equipment	0001213900-25-030318	1	monetary	D	D	Noncash Purchase Of Property And Equipment	Non-cash purchase of property and equipment.
Payment To Release Ofinvestment In Restricted Deposits	0001213900-25-030318	1	monetary	D	D	Payment To Release Ofinvestment In Restricted Deposits	The amount of release of investment in restricted deposits.
Accounts And Other Receivables Net Current	us-gaap/2024	0	monetary	I	D	Accounts and Other Receivables, Net, Current	Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.
Cash And Cash Equivalents At Carrying Value	us-gaap/2024	0	monetary	I	D	Cash and Cash Equivalents, at Carrying Value	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
Dividends And Interest Paid	us-gaap/2024	0	monetary	D	D	Dividends and Interest Paid	The contractual amount of dividends (or interest on participating income bonds) that must be paid for the current period (for example, unpaid cumulative dividends).
Foreign Currency Transaction Gain Loss Before Tax	us-gaap/2024	0	monetary	D	C	Gain (Loss), Foreign Currency Transaction, before Tax	Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.
Income Taxes Paid Net	us-gaap/2024	0	monetary	D	C	Income Taxes Paid, Net	Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.
Increase Decrease In Inventories	us-gaap/2024	0	monetary	D	C	Increase (Decrease) in Inventories	The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets	us-gaap/2024	0	monetary	D	C	Increase (Decrease) in Prepaid Expense and Other Assets	Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Other Comprehensive Income Loss Net Of Tax	us-gaap/2024	0	monetary	D	C	Other Comprehensive Income (Loss), Net of Tax	Amount after tax and reclassification adjustments of other comprehensive income (loss).
Other Liabilities Current	us-gaap/2024	0	monetary	I	C	Other Liabilities, Current	Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
Stock Issued During Period Shares Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A Il Ltd	0001213900-25-030318	1	shares	D		Stock Issued During Period Shares Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox AIl Ltd	Number of shares issuance of ordinary shares under a settlement agreement with former shareholders of Nanox AI Ltd.
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	us-gaap/2024	0	monetary	D	C	APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
Deferred Income Tax Expense Benefit	us-gaap/2024	0	monetary	D	D	Deferred Income Tax Expense (Benefit)	Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Deposits Assets Current	us-gaap/2024	0	monetary	I	D	Deposits Assets, Current	Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.
Increase Decrease In Accrued Liabilities And Other Operating Liabilities	us-gaap/2024	0	monetary	D	D	Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities	Amount of increase (decrease) in accrued expenses, and obligations classified as other.
Finite Lived Intangible Assets Net	us-gaap/2024	0	monetary	I	D	Finite-Lived Intangible Assets, Net	Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
Liabilities Noncurrent	us-gaap/2024	0	monetary	I	C	Liabilities, Noncurrent	Amount of obligation due after one year or beyond the normal operating cycle, if longer.
Net Cash Provided By Used In Operating Activities	us-gaap/2024	0	monetary	D		Net Cash Provided by (Used in) Operating Activities	Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses	us-gaap/2024	0	monetary	D	D	Operating Expenses	Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss	us-gaap/2024	0	monetary	D	C	Operating Income (Loss)	The net result for the period of deducting operating expenses from operating revenues.
Other Assets Current	us-gaap/2024	0	monetary	I	D	Other Assets, Current	Amount of current assets classified as other.
Other Liabilities Noncurrent	us-gaap/2024	0	monetary	I	C	Other Liabilities, Noncurrent	Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Proceeds From Sale Of Held To Maturity Securities	us-gaap/2024	0	monetary	D	D	Proceeds from Sale of Held-to-Maturity Securities	The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.
Restricted Cash Noncurrent	us-gaap/2024	0	monetary	I	D	Restricted Cash, Noncurrent	Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.
Stock Issued During Period Shares Other	us-gaap/2024	0	shares	D		Stock Issued During Period, Shares, Other	Number of shares of stock issued attributable to transactions classified as other.
Temporary Equity Shares Outstanding	us-gaap/2024	0	shares	I		Temporary Equity, Shares Outstanding	The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.
Reclassification Of Earnout Liability To Equity	0001213900-25-030318	1	monetary	D	C	Reclassification Of Earnout Liability To Equity	Reclassification of earn out liability to equity.
Common Stock Value	us-gaap/2024	0	monetary	I	C	Common Stock, Value, Issued	Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
General And Administrative Expense	us-gaap/2024	0	monetary	D	D	General and Administrative Expense	The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Inventory Net	us-gaap/2024	0	monetary	I	D	Inventory, Net	Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Research And Development Expense	us-gaap/2024	0	monetary	D	D	Research and Development Expense	Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Revenues	us-gaap/2024	0	monetary	D	C	Revenues	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Issuance Of Ordinary Shares Upon Exercise Of R S Usin Share	0001213900-25-030318	1	shares	D		Issuance Of Ordinary Shares Upon Exercise Of RSUsin Share	Issuance of ordinary shares upon exercise of RSU.
Payment Due To Settlement Of Contingent Earnout Liabilities	0001213900-25-030318	1	monetary	D	C	Payment Due To Settlement Of Contingent Earnout Liabilities	Payment due to settlement of contingent earnout liabilities.
Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	0001213900-25-030318	1	monetary	D	C	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox AILtd	Value of stock issued during the period ordinary shares under a settlement agreement with former shareholders of Nanox AI Ltd.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	us-gaap/2024	0	monetary	I	D	Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations	Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Accounts Payable Current	us-gaap/2024	0	monetary	I	C	Accounts Payable, Current	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Additional Paid In Capital Common Stock	us-gaap/2024	0	monetary	I	C	Additional Paid in Capital, Common Stock	Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
Amortization Of Intangible Assets	us-gaap/2024	0	monetary	D	D	Amortization of Intangible Assets	The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Assets Noncurrent	us-gaap/2024	0	monetary	I	D	Assets, Noncurrent	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect	us-gaap/2024	0	monetary	D	D	Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies	us-gaap/2024	0	monetary	I	C	Commitments and Contingencies	Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized	us-gaap/2024	0	shares	I		Common Stock, Shares Authorized	The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Deferred Income Tax Liabilities Net	us-gaap/2024	0	monetary	I	C	Deferred Income Tax Liabilities, Net	Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.
Gain Loss On Sale Of Property Plant Equipment	us-gaap/2024	0	monetary	D	C	Gain (Loss) on Disposition of Property Plant Equipment	Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
Net Cash Provided By Used In Financing Activities	us-gaap/2024	0	monetary	D	D	Net Cash Provided by (Used in) Financing Activities	Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Asset Impairment Charges	us-gaap/2024	0	monetary	D	D	Other Asset Impairment Charges	The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.
Contract With Customer Liability Current	us-gaap/2024	0	monetary	I	C	Contract with Customer, Liability, Current	Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.
Depreciation	us-gaap/2024	0	monetary	D	D	Depreciation	The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Earnings Per Share Basic	us-gaap/2024	0	perShare	D		Earnings Per Share, Basic	The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets	0001213900-25-030318	1	monetary	D	C	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets
Net Cash Provided By Used In Investing Activities	us-gaap/2024	0	monetary	D	D	Net Cash Provided by (Used in) Investing Activities	Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Payments Of Financing Costs	us-gaap/2024	0	monetary	D	C	Payments of Financing Costs	The cash outflow for loan and debt issuance costs.
Payments To Acquire Marketable Securities	us-gaap/2024	0	monetary	D	C	Payments to Acquire Marketable Securities	Amount of cash outflow for purchase of marketable security.
Proceeds From Issuance Of Common Stock	us-gaap/2024	0	monetary	D	D	Proceeds from Issuance of Common Stock	The cash inflow from the additional capital contribution to the entity.
Stock Issued During Period Shares Stock Options Exercised	us-gaap/2024	0	shares	D		Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period	Number of share options (or share units) exercised during the current period.
Proceeds From Short Term Deposits	0001213900-25-030318	1	monetary	D	C	Proceeds From Short Term Deposits	Amount proceeds from short term deposits.
Stock Issued During Period Shares Ordinary Shares In Connection With Earnout Liability	0001213900-25-030318	1	shares	D		Stock Issued During Period Shares Ordinary Shares In Connection With Earnout Liability	Number of share issuance of ordinary shares in connection with earned liability.
Stock Issued During Period Shares Ordinary Shares Upon Exercise Of Warrants	0001213900-25-030318	1	shares	D		Stock Issued During Period Shares Ordinary Shares Upon Exercise Of Warrants	Number of shares, stocks issued during the period ordinary shares upon exercise of warrants
Deposits Assets Noncurrent	us-gaap/2024	0	monetary	I	D	Deposits Assets, Noncurrent	Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.
Increase Decrease In Other Noncurrent Liabilities	us-gaap/2024	0	monetary	D	D	Increase (Decrease) in Other Noncurrent Liabilities	Amount of increase (decrease) in noncurrent operating liabilities classified as other.
Long Term Debt Current	us-gaap/2024	0	monetary	I	C	Long-Term Debt, Current Maturities	Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.
Operating Lease Liability Noncurrent	us-gaap/2024	0	monetary	I	C	Operating Lease, Liability, Noncurrent	Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Proceeds From Warrant Exercises	us-gaap/2024	0	monetary	D	D	Proceeds from Warrant Exercises	The cash inflow associated with the amount received from holders exercising their stock warrants.
Stock Issued During Period Shares Acquisitions	us-gaap/2024	0	shares	D		Stock Issued During Period, Shares, Acquisitions	Number of shares of stock issued during the period pursuant to acquisitions.
Stock Issued During Period Value Other	us-gaap/2024	0	monetary	D	C	Stock Issued During Period, Value, Other	Value of shares of stock issued attributable to transactions classified as other.
Weighted Average Number Of Shares Outstanding Basic	us-gaap/2024	0	shares	D		Weighted Average Number of Shares Outstanding, Basic	Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Property Plant And Equipment Net	us-gaap/2024	0	monetary	I	D	Property, Plant and Equipment, Net	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

Description

Field Name	Field Description
tag	The unique identifier (name) for a tag in a specific taxonomy release.
version	For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom	1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract	1 if the tag is not used to represent a numeric fact.
datatype	If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord	If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr	If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel	If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc	The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh	report	line	stmt	inpth	rfile	tag	version	plabel	negating
0001213900-25-030318	5	11	IS	0	H	Operating Expenses	us-gaap/2024	TOTAL OPERATING EXPENSES	0
0001213900-25-030318	3	3	BS	0	H	Cash And Cash Equivalents At Carrying Value	us-gaap/2024	Cash and cash equivalents	0
0001213900-25-030318	3	4	BS	0	H	Restricted Cash Current	us-gaap/2024	Restricted deposit	0
0001213900-25-030318	3	5	BS	0	H	Deposits Assets Current	us-gaap/2024	Short-term deposits	0
0001213900-25-030318	3	6	BS	0	H	Marketable Securities Current	us-gaap/2024	Marketable securities	0
0001213900-25-030318	3	7	BS	0	H	Accounts And Other Receivables Net Current	us-gaap/2024	Accounts receivables net of allowance for credit losses of $112 and $55 as of December 31, 2024 and December 31,2023, respectively.	0
0001213900-25-030318	3	8	BS	0	H	Inventory Net	us-gaap/2024	Inventories	0
0001213900-25-030318	3	9	BS	0	H	Prepaid Expense Current	us-gaap/2024	Prepaid expenses	0
0001213900-25-030318	3	10	BS	0	H	Other Assets Current	us-gaap/2024	Other current assets	0
0001213900-25-030318	3	11	BS	0	H	Assets Current	us-gaap/2024	TOTAL CURRENT ASSETS	0
0001213900-25-030318	3	13	BS	0	H	Restricted Cash Noncurrent	us-gaap/2024	Restricted deposit	0
0001213900-25-030318	3	14	BS	0	H	Deposits Assets Noncurrent	us-gaap/2024	Long-term deposits	0
0001213900-25-030318	3	15	BS	0	H	Property Plant And Equipment Net	us-gaap/2024	Property and equipment, net	0
0001213900-25-030318	3	16	BS	0	H	Operating Lease Right Of Use Asset	us-gaap/2024	Operating lease right-of-use asset	0
0001213900-25-030318	3	17	BS	0	H	Finite Lived Intangible Assets Net	us-gaap/2024	Intangible assets	0
0001213900-25-030318	3	18	BS	0	H	Other Assets Noncurrent	us-gaap/2024	Other non-current assets	0
0001213900-25-030318	3	19	BS	0	H	Assets Noncurrent	us-gaap/2024	TOTAL NON-CURRENT ASSETS	0
0001213900-25-030318	3	20	BS	0	H	Assets	us-gaap/2024	TOTAL ASSETS	0
0001213900-25-030318	3	23	BS	0	H	Long Term Debt Current	us-gaap/2024	Current maturities of long term loan	0
0001213900-25-030318	3	24	BS	0	H	Accounts Payable Current	us-gaap/2024	Accounts payable	0
0001213900-25-030318	3	25	BS	0	H	Accrued Liabilities Current	us-gaap/2024	Accrued expenses	0
0001213900-25-030318	3	26	BS	0	H	Contract With Customer Liability Current	us-gaap/2024	Deferred revenue	0
0001213900-25-030318	3	27	BS	0	H	Operating Lease Liability Current	us-gaap/2024	Current maturities of operating lease liabilities	0
0001213900-25-030318	3	28	BS	0	H	Other Liabilities Current	us-gaap/2024	Other current liabilities	0
0001213900-25-030318	3	29	BS	0	H	Liabilities Current	us-gaap/2024	TOTAL CURRENT LIABILITIES	0
0001213900-25-030318	3	31	BS	0	H	Operating Lease Liability Noncurrent	us-gaap/2024	Non-current operating lease liabilities	0
0001213900-25-030318	3	32	BS	0	H	Deferred Income Tax Liabilities Net	us-gaap/2024	Deferred tax liability	0
0001213900-25-030318	3	33	BS	0	H	Other Liabilities Noncurrent	us-gaap/2024	Other long-term liabilities	0
0001213900-25-030318	3	34	BS	0	H	Liabilities Noncurrent	us-gaap/2024	TOTAL NON-CURRENT LIABILITIES	0
0001213900-25-030318	3	35	BS	0	H	Liabilities	us-gaap/2024	TOTAL LIABILITIES	0
0001213900-25-030318	3	36	BS	0	H	Commitments And Contingencies	us-gaap/2024	COMMITMENTS AND CONTINGENCIES	0
0001213900-25-030318	3	38	BS	0	H	Common Stock Value	us-gaap/2024	Ordinary Shares, par value NIS 0.01 per share 100,000,000 authorized at December 31, 2024 and December 31 2023, 63,762,001 and 57,778,628 issued and outstanding at December 31, 2024 and December 31, 2023, respectively	0
0001213900-25-030318	3	39	BS	0	H	Additional Paid In Capital Common Stock	us-gaap/2024	Additional paid-in capital	0
0001213900-25-030318	3	40	BS	0	H	Accumulated Other Comprehensive Income Loss Net Of Tax	us-gaap/2024	Accumulated other comprehensive loss	0
0001213900-25-030318	3	41	BS	0	H	Retained Earnings Accumulated Deficit	us-gaap/2024	Accumulated deficit	0
0001213900-25-030318	3	42	BS	0	H	Stockholders Equity	us-gaap/2024	TOTAL SHAREHOLDERS EQUITY	0
0001213900-25-030318	3	43	BS	0	H	Liabilities And Stockholders Equity	us-gaap/2024	TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	0
0001213900-25-030318	4	1	BS	1	H	Accounts Receivable Net	us-gaap/2024	Accounts receivables net, credit losses (in Dollars)	0
0001213900-25-030318	4	2	BS	1	H	Common Stock Par Or Stated Value Per Share	us-gaap/2024	Ordinary Shares, par value (in New Shekels per share)	0
0001213900-25-030318	4	3	BS	1	H	Common Stock Shares Authorized	us-gaap/2024	Ordinary shares, shares authorized	0
0001213900-25-030318	4	4	BS	1	H	Common Stock Shares Issued	us-gaap/2024	Ordinary shares, shares issued	0
0001213900-25-030318	4	5	BS	1	H	Temporary Equity Shares Outstanding	us-gaap/2024	Ordinary shares, shares outstanding	0
0001213900-25-030318	5	1	IS	0	H	Revenues	us-gaap/2024	REVENUE	0
0001213900-25-030318	5	2	IS	0	H	Cost Of Revenue	us-gaap/2024	COST OF REVENUE	0
0001213900-25-030318	5	3	IS	0	H	Gross Profit	us-gaap/2024	GROSS LOSS	0
0001213900-25-030318	5	5	IS	0	H	Research And Development Expense	us-gaap/2024	Research and development, net	0
0001213900-25-030318	5	6	IS	0	H	Selling And Marketing Expense	us-gaap/2024	Sales and Marketing	0
0001213900-25-030318	5	7	IS	0	H	General And Administrative Expense	us-gaap/2024	General and administrative	0
0001213900-25-030318	5	8	IS	0	H	Goodwill Impairment Loss	us-gaap/2024	Goodwill impairment	0
0001213900-25-030318	5	9	IS	0	H	Change In Contingent Earnout Liability	0001213900-25-030318	Change in contingent earnout liability	1
0001213900-25-030318	5	10	IS	0	H	Other Operating Income Expense Net	us-gaap/2024	Other expenses (income)	1
0001213900-25-030318	5	12	IS	0	H	Operating Income Loss	us-gaap/2024	OPERATING LOSS	0
0001213900-25-030318	5	13	IS	0	H	Gain Loss On Investments	us-gaap/2024	REALIZED INCOME (LOSS) FROM SALE OF MARKETABLE SECURITIES	0
0001213900-25-030318	5	14	IS	0	H	Interest Income Expense Nonoperating Net	us-gaap/2024	FINANCIAL INCOME, net	0
0001213900-25-030318	5	15	IS	0	H	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest	us-gaap/2024	OPERATING LOSS BEFORE INCOME TAXES	0
0001213900-25-030318	5	16	IS	0	H	Income Tax Expense Benefit	us-gaap/2024	INCOME TAX BENEFIT	1
0001213900-25-030318	5	17	IS	0	H	Net Income Loss	us-gaap/2024	NET LOSS	0
0001213900-25-030318	5	18	IS	0	H	Earnings Per Share Basic	us-gaap/2024	BASIC LOSS PER SHARE (in Dollars per share)	0
0001213900-25-030318	5	19	IS	0	H	Earnings Per Share Diluted	us-gaap/2024	DILUTED LOSS PER SHARE (in Dollars per share)	0
0001213900-25-030318	5	20	IS	0	H	Weighted Average Number Of Shares Outstanding Basic	us-gaap/2024	WEIGHTED AVERAGE NUMBER OF BASIC ORDINARY SHARES OUTSTANDING (IN THOUSANDS) (in Shares)	0
0001213900-25-030318	5	21	IS	0	H	Weighted Average Number Of Diluted Shares Outstanding	us-gaap/2024	WEIGHTED AVERAGE NUMBER OF DILUTED ORDINARY SHARES OUTSTANDING (IN THOUSANDS) (in Shares)	0
0001213900-25-030318	5	22	IS	0	H	Net Income Loss	us-gaap/2024	NET LOSS	0
0001213900-25-030318	5	24	IS	0	H	Other Comprehensive Income Loss Before Reclassifications Net Of Tax	us-gaap/2024	Reclassification of net losses (income) realized in income statement	0
0001213900-25-030318	5	25	IS	0	H	Marketable Securities Unrealized Gain Loss	us-gaap/2024	Unrealized gain (loss) from marketable securities	0
0001213900-25-030318	5	26	IS	0	H	Other Comprehensive Income Loss Net Of Tax	us-gaap/2024	Total other comprehensive income (loss):	0
0001213900-25-030318	5	27	IS	0	H	Comprehensive Income Net Of Tax	us-gaap/2024	TOTAL COMPREHENSIVE LOSS	0
0001213900-25-030318	6	9	EQ	0	H	Stockholders Equity	us-gaap/2024	Balance	0
0001213900-25-030318	6	10	EQ	0	H	Common Stock Shares Outstanding	us-gaap/2024	Balance (in Shares)	0
0001213900-25-030318	6	11	EQ	0	H	Stock Issued During Period Value Other	us-gaap/2024	Issuance of ordinary shares and warrants, net of issuance expenses	0
0001213900-25-030318	6	12	EQ	0	H	Stock Issued During Period Shares Other	us-gaap/2024	Issuance of ordinary shares and warrants, net of issuance expenses (in Shares)	0
0001213900-25-030318	6	13	EQ	0	H	Issuance Of Ordinary Shares Upon Exercise Of R S Usin Share	0001213900-25-030318	Issuance of ordinary shares upon exercise of RSUs (in Shares)	0
0001213900-25-030318	6	14	EQ	0	H	Reclassifications Of Temporary To Permanent Equity	us-gaap/2024	Reclassification of earn-out liability to equity	0
0001213900-25-030318	6	15	EQ	0	H	Issuance Of Ordinary Shares To Investors Sue To Business Combination And Purchase Of Assets	0001213900-25-030318	Issuance of ordinary shares due to business combination and assets acquisition	0
0001213900-25-030318	6	16	EQ	0	H	Stock Issued During Period Shares Acquisitions	us-gaap/2024	Issuance of ordinary shares due to business combination and assets acquisition (in Shares)	0
0001213900-25-030318	6	17	EQ	0	H	Issuance Of Ordinary Shares Upon Exercise Of R S Us	0001213900-25-030318	Issuance of ordinary shares upon exercise of RSUs	0
0001213900-25-030318	6	18	EQ	0	H	Issuance Of Ordinary Shares Upon Exercise Of R S Usin Shares	0001213900-25-030318	Issuance of ordinary shares upon exercise of RSUs (in Shares)	0
0001213900-25-030318	6	19	EQ	0	H	Issuance Of Ordinary Shares Value Upon Exercise Of Warrants	0001213900-25-030318	Issuance of ordinary shares upon exercise of warrants	0
0001213900-25-030318	6	20	EQ	0	H	Stock Issued During Period Shares Ordinary Shares Upon Exercise Of Warrants	0001213900-25-030318	Issuance of ordinary shares upon exercise of warrants (in Shares)	0
0001213900-25-030318	6	21	EQ	0	H	Stock Issued During Period Value Stock Options Exercised	us-gaap/2024	Issuance of ordinary shares upon exercise of options	0
0001213900-25-030318	6	22	EQ	0	H	Stock Issued During Period Shares Stock Options Exercised	us-gaap/2024	Issuance of ordinary shares upon exercise of options (in Shares)	0
0001213900-25-030318	6	23	EQ	0	H	Stock Issued During Period Ordinary Shares In Connection With Earnout Liability	0001213900-25-030318	Issuance of ordinary shares in connection with earnout liability. (refer to Note 3)	0
0001213900-25-030318	6	24	EQ	0	H	Stock Issued During Period Shares Ordinary Shares In Connection With Earnout Liability	0001213900-25-030318	Issuance of ordinary shares in connection with earnout liability. (refer to Note 3) (in Shares)	0
0001213900-25-030318	6	25	EQ	0	H	Stock Issued During Period Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A I Ltd	0001213900-25-030318	Issuance of ordinary shares under settlement agreement with former shareholders	0
0001213900-25-030318	6	26	EQ	0	H	Stock Issued During Period Shares Ordinary Shares Under Settlement Agreement With Former Shareholders Of Nanox A Il Ltd	0001213900-25-030318	Issuance of ordinary shares under settlement agreement with former shareholders (in Shares)	0
0001213900-25-030318	6	27	EQ	0	H	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition	us-gaap/2024	Share-based compensation	0
0001213900-25-030318	6	28	EQ	0	H	Unrealized Loss From Availableforsale Securities	0001213900-25-030318	Unrealized gain from marketable securities, net	0
0001213900-25-030318	6	29	EQ	0	H	Net Income Loss	us-gaap/2024	Net loss for the year	0
0001213900-25-030318	6	30	EQ	0	H	Stockholders Equity	us-gaap/2024	Balance	0
0001213900-25-030318	6	31	EQ	0	H	Common Stock Shares Outstanding	us-gaap/2024	Balance (in Shares)	0
0001213900-25-030318	7	2	CF	0	H	Net Income Loss	us-gaap/2024	Net loss for the year	0
0001213900-25-030318	7	4	CF	0	H	Share Based Compensation	us-gaap/2024	Share-based compensation	0
0001213900-25-030318	7	5	CF	0	H	Amortization Of Intangible Assets	us-gaap/2024	Amortization of intangible assets	0
0001213900-25-030318	7	6	CF	0	H	Goodwill Impairment Loss	us-gaap/2024	Impairment of goodwill	0
0001213900-25-030318	7	7	CF	0	H	Change In Contingent Earnout Liability	0001213900-25-030318	Change in contingent earnout liability	1
0001213900-25-030318	7	8	CF	0	H	Depreciation	us-gaap/2024	Depreciation	0
0001213900-25-030318	7	9	CF	0	H	Deferred Income Tax Expense Benefit	us-gaap/2024	Deferred tax liability, net	0
0001213900-25-030318	7	10	CF	0	H	Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments	us-gaap/2024	Realized loss (income) from sale of marketable securities	1
0001213900-25-030318	7	11	CF	0	H	Foreign Currency Transaction Gain Loss Before Tax	us-gaap/2024	Exchange rate differentials	1
0001213900-25-030318	7	12	CF	0	H	Amortization Of Premium Discount And Accrued Interest On Marketable Securities	0001213900-25-030318	Amortization of premium, discount and accrued interest on marketable securities	1
0001213900-25-030318	7	13	CF	0	H	Other Asset Impairment Charges	us-gaap/2024	Impairment of property and equipment	0
0001213900-25-030318	7	14	CF	0	H	Gain Loss On Sale Of Property Plant Equipment	us-gaap/2024	Loss from disposal of property and equipment	1
0001213900-25-030318	7	16	CF	0	H	Increase Decrease In Inventories	us-gaap/2024	Change in inventories	1
0001213900-25-030318	7	17	CF	0	H	Increase Decrease In Receivables	us-gaap/2024	Accounts receivable, net	1
0001213900-25-030318	7	18	CF	0	H	Increase Decrease In Prepaid Deferred Expense And Other Assets	us-gaap/2024	Prepaid expenses and other current assets	1
0001213900-25-030318	7	19	CF	0	H	Increase Decrease In Other Noncurrent Assets	us-gaap/2024	Other non-current assets	1
0001213900-25-030318	7	20	CF	0	H	Increase Decrease In Accounts Payable Trade	us-gaap/2024	Accounts payable	0
0001213900-25-030318	7	21	CF	0	H	Increase Decrease In Accrued Liabilities And Other Operating Liabilities	us-gaap/2024	Accrued expenses and other liabilities	0
0001213900-25-030318	7	22	CF	0	H	Increase Decrease In Other Operating Capital Net	us-gaap/2024	Operating lease assets and liabilities	1
0001213900-25-030318	7	23	CF	0	H	Increase Decrease In Contract With Customer Liability	us-gaap/2024	Deferred revenue	0
0001213900-25-030318	7	24	CF	0	H	Increase Decrease In Other Noncurrent Liabilities	us-gaap/2024	Other long-term liabilities	0
0001213900-25-030318	7	25	CF	0	H	Net Cash Provided By Used In Operating Activities	us-gaap/2024	Net cash used in operating activities	0
0001213900-25-030318	7	27	CF	0	H	Payment To Release Ofinvestment In Restricted Deposits	0001213900-25-030318	Release of (investment in) restricted deposits	0
0001213900-25-030318	7	28	CF	0	H	Proceeds From Sale Of Held To Maturity Securities	us-gaap/2024	Proceeds from maturity of marketable securities	0
0001213900-25-030318	7	29	CF	0	H	Payments To Acquire Marketable Securities	us-gaap/2024	Purchase of marketable securities	1
0001213900-25-030318	7	30	CF	0	H	Proceeds From Sale And Maturity Of Marketable Securities	us-gaap/2024	Proceeds from sale of marketable securities	0
0001213900-25-030318	7	31	CF	0	H	Proceeds From Short Term Deposits	0001213900-25-030318	Investment in short-term deposits	1
0001213900-25-030318	7	32	CF	0	H	Proceeds From Long Term Deposits	0001213900-25-030318	Investment in long-term deposits	1
0001213900-25-030318	7	33	CF	0	H	Payments To Acquire Property Plant And Equipment	us-gaap/2024	Purchase of property and equipment	1
0001213900-25-030318	7	34	CF	0	H	Payments To Acquire Equity Method Investments	us-gaap/2024	Investment in equity securities	1
0001213900-25-030318	7	35	CF	0	H	Net Cash Provided By Used In Investing Activities	us-gaap/2024	Net cash provided by (used in) investing activities	0
0001213900-25-030318	7	37	CF	0	H	Proceeds From Issuance Of Common Stock	us-gaap/2024	Proceeds from issuance of ordinary shares and warrants, net of issuance costs	0
0001213900-25-030318	7	38	CF	0	H	Payments Of Financing Costs	us-gaap/2024	Repayment of financial liability	1
0001213900-25-030318	7	39	CF	0	H	Payment Due To Settlement Of Contingent Earnout Liabilities	0001213900-25-030318	Payment due to settlement of contingent earnout liabilities	1
0001213900-25-030318	7	40	CF	0	H	Proceeds From Warrant Exercises	us-gaap/2024	Proceeds from issuance of ordinary shares upon exercise of warrants	0
0001213900-25-030318	7	41	CF	0	H	Proceeds From Stock Options Exercised	us-gaap/2024	Proceeds from issuance of ordinary shares upon exercise of options	0
0001213900-25-030318	7	42	CF	0	H	Net Cash Provided By Used In Financing Activities	us-gaap/2024	Net cash provided by financing activities	0
0001213900-25-030318	7	43	CF	0	H	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	us-gaap/2024	EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS	0
0001213900-25-030318	7	44	CF	0	H	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect	us-gaap/2024	NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS	0
0001213900-25-030318	7	45	CF	0	H	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	us-gaap/2024	CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT BEGINNING OF THE YEAR	0
0001213900-25-030318	7	46	CF	0	H	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations	us-gaap/2024	CASH AND CASH EQUIVALENTS AND RESTRICTED CASH EQUIVALENTS AT END OF THE YEAR	0
0001213900-25-030318	7	48	CF	0	H	Income Taxes Paid Net	us-gaap/2024	Cash paid for income taxes	0
0001213900-25-030318	7	49	CF	0	H	Dividends And Interest Paid	us-gaap/2024	Cash paid for interest	0
0001213900-25-030318	7	51	CF	0	H	Issuance Of Ordinary Share In Connections With Earnout Liability	0001213900-25-030318	Issuance of ordinary shares in connection with earnout liability	0
0001213900-25-030318	7	52	CF	0	H	Issuance Of Ordinary Shares Under Settlement Agreement With Former Shareholders	0001213900-25-030318	Issuance of ordinary shares under settlement agreement with former shareholders of Nanox AI Ltd.	0
0001213900-25-030318	7	53	CF	0	H	Reclassification Of Earnout Liability To Equity	0001213900-25-030318	Reclassification of earn-out liability to equity	0
0001213900-25-030318	7	54	CF	0	H	Noncash Purchase Of Property And Equipment	0001213900-25-030318	Non-cash purchase of property and equipment	0
0001213900-25-030318	7	55	CF	0	H	Operating Lease Liabilities Arising From Obtaining Operating Rightof Use Assets1	0001213900-25-030318	Operating lease liabilities arising from obtaining operating right-of use assets	0

Description

Field Name	Field Description
adsh	Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report	Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line	Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt	The financial statement location to which the value of the “report” field pertains.
inpth	Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile	The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag	The tag chosen by the filer for this line item.
version	The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel	The text presented on the line item, also known as a “preferred” label.
negating	Flag to indicate whether the plabel is negating.